427 related articles for article (PubMed ID: 25848479)
1. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.
Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
World J Hepatol; 2015 Mar; 7(3):559-65. PubMed ID: 25848479
[TBL] [Abstract][Full Text] [Related]
2. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
Meroni M; Longo M; Dongiovanni P
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
[TBL] [Abstract][Full Text] [Related]
3. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.
Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
Nutrients; 2014 Dec; 6(12):5583-99. PubMed ID: 25479248
[TBL] [Abstract][Full Text] [Related]
4. Probiotics and Nonalcoholic Fatty liver Disease.
Eslamparast T; Eghtesad S; Hekmatdoost A; Poustchi H
Middle East J Dig Dis; 2013 Jul; 5(3):129-36. PubMed ID: 24829682
[TBL] [Abstract][Full Text] [Related]
5. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms.
Iacono A; Raso GM; Canani RB; Calignano A; Meli R
J Nutr Biochem; 2011 Aug; 22(8):699-711. PubMed ID: 21292470
[TBL] [Abstract][Full Text] [Related]
6. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
7. Obesity and NAFLD: the role of bacteria and microbiota.
Duseja A; Chawla YK
Clin Liver Dis; 2014 Feb; 18(1):59-71. PubMed ID: 24274865
[TBL] [Abstract][Full Text] [Related]
8. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
9. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease.
Augustyn M; Grys I; Kukla M
Clin Exp Hepatol; 2019 Mar; 5(1):1-10. PubMed ID: 30915401
[TBL] [Abstract][Full Text] [Related]
10. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
11. Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease.
Mijangos-Trejo A; Nuño-Lambarri N; Barbero-Becerra V; Uribe-Esquivel M; Vidal-Cevallos P; Chávez-Tapia N
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834367
[TBL] [Abstract][Full Text] [Related]
12. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD.
Perumpail BJ; Li AA; John N; Sallam S; Shah ND; Kwong W; Cholankeril G; Kim D; Ahmed A
Diseases; 2019 Feb; 7(1):. PubMed ID: 30823570
[TBL] [Abstract][Full Text] [Related]
13. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
[TBL] [Abstract][Full Text] [Related]
14. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
15. Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction.
Thilakarathna WPDW; Rupasinghe HPV
Molecules; 2024 Feb; 29(3):. PubMed ID: 38338453
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
Li DY; Yang M; Edwards S; Ye SQ
JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
[TBL] [Abstract][Full Text] [Related]
17. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
18. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
20. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
